Valeant Pharma (VRX) Reports Q1 Revenues Above Estimates; Boosts FY18 Revenue & EBITDA Outlook
Valeant Pharma (NYSE: VRX) reported Q1 EPS of ($7.68), versus $0.60 reported last year. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.95 billion.
- Outperformed Expectations in the First Quarter of 2018
- Revenues of $1.995 Billion
- GAAP Net Loss of $2.693 Billion
- GAAP Cash Flow from Operations of $438 Million
- Adjusted EBITDA (non-GAAP)1 of $832 Million
- Delivered Overall Organic Revenue Growth2 for the First Time since 2015, Driven by Branded Rx and Bausch + Lomb/International Segments
- Raised 2018 Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges
- Company\'s Name Will Change to Bausch Health Companies Inc. in July 2018
GUIDANCE:
Valeant Pharma sees FY2018 revenue of $8.15-8.35 billion, versus the consensus of $8.24 billion.
For earnings history and earnings-related data on Valeant Pharma (VRX) click here.